Many patients in trial lost an average of 16 pounds in just nine months.

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

A new pill designed to help with weight loss and blood sugar control is showing promise in early studies. Eli Lilly said its ...

The first daily weight-loss pill is expected to be available in the UK as soon as 2026 after a trial found it to be effective ...

A new weight-loss pill taken daily could compete with injections like Ozempic, research suggests. Patients, who all were ...

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

Fridays offers a subscription-based weight loss service. Its program includes virtual consultations with a health care provider, compounded GLP-1 medications, lifestyle and nutrition coaching, and ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly and Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot.

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...